Abstracts tagged "Comorbidity"

Abstract Number: 528 • 2017 ACR/ARHP Annual Meeting
Impact of Comorbidities on the Occurrence of Infections in Rheumatoid Arthritis Treated By Biologic Agents
Christopher Banse¹, Nicolas Chrin², Pascal Rottenberg³, Sophie Pouplin⁴, thierry Lequerre⁵ and Olivier Vittecoq³, ¹Rheumatology, Rouen University Hospital, Rouen, France, ²Department of Biostatistics, Rouen University Hospital, 76031 Rouen, France, ROUEN, France, ³INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, ⁴Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ⁵Rheumatology Department, Rouen University Hospital, University of Rouen, 76031 Rouen, France., ROUEN, France
Background/Purpose: to investigate the potential relationship between the number of comorbidities at initiation of biotherapy and the occurrence of a severe infection or recurrent infections…
Abstract Number: 1004 • 2017 ACR/ARHP Annual Meeting
Arthritis Impact at the State and County Level — United States, 2015
Kamil E. Barbour¹, Suson Moss², Janet Croft², Jennifer M. Hootman³, Louise Murphy⁴, Kristina Theis², Yan Wang², Hua Lu², Teresa J. Brady¹ and Charles G. Helmick², ¹Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA, ²Centers for Disease Control and Prevention, Atlanta, GA, ³Centers for Disease Control and Prevention, Kennesaw, GA, ⁴Division of Population Health, Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: Arthritis, a leading cause of disability, affects 54.4 million US adults. By knowing the state and county level arthritis impact, state-level public health professionals…
Abstract Number: 1036 • 2017 ACR/ARHP Annual Meeting
Blood Glucose Changes Surrounding Initiation of Tumor-Necrosis Factor Inhibitors and Conventional Disease-Modifying Anti-Rheumatic Drugs in Veterans with Rheumatoid Arthritis
Patrick R. Wood¹, Evan Manning², Joshua Baker³, Grant Cannon⁴, Lisa Davis⁵, Bryant R. England⁶, Ted R. Mikuls⁷ and Liron Caplan⁸, ¹Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO, ³Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁴Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁵Div of Rheumatology, Denver Health, Denver, CO, ⁶Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁷Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁸Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: There is evidence linking activation of the innate immune system and insulin resistance. Perturbations in glucose homeostasis upon initiation of tumor-necrosis factor inhibitors (TNFis)…
Abstract Number: 1527 • 2017 ACR/ARHP Annual Meeting
Do TNF Inhibitors Alter the Natural History of Ankylosing Spondylitis By Impacting the Incidence and Prevalence of Comorbidities and Extra-Articular Manifestations?
Atul A. Deodhar¹, Kevin Winthrop², Benjamin Chan², Sarah A. R. Siegel², Lisa Pisenti³, Jeffrey Stark³, Robert Y. Suruki⁴, Rhonda L. Bohn⁴, Huifeng Yun⁵, Lang Chen⁵ and Jeffrey R. Curtis⁵, ¹Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, ²Oregon Health & Science University, Portland, OR, ³UCB Pharma, Smyrna, GA, ⁴UCB Pharma, Raleigh, NC, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Treatment with TNF inhibitors (TNFi) has led to a reduction in signs and symptoms, and improvement in physical function and quality of life in…
Abstract Number: 111 • 2016 ACR/ARHP Annual Meeting
Influences of Osteoarthritis Pain, Comorbid Insomnia, and Depression on Health Care Use in Older Adults with Osteoarthritis
Minhui Liu¹, Susan M. McCurry¹, Michael V. Vitiello², Basia Belza¹ and Michael Von Korff³, ¹University of Washington School of Nursing, Seattle, WA, ²Psychiatry and Behavioral Sciences, Biobehavioral Nursing and Health Systems, University of Washington School of Medicine, Seattle, WA, ³Group Health Research Institute, Seattle, WA
Background/Purpose: Osteoarthritis (OA), the most common type of arthritis, is prevalent and costly. Pain is the principal reason patients with OA seek treatment. Older adults…
Abstract Number: 899 • 2016 ACR/ARHP Annual Meeting
Disparities in Disease Characteristics, Treatment Pattern and Comorbidities in 1,858 Patients with Polymyalgia Rheumatica, Giant Cell Arteritis or Both Diseases
Dörte Huscher¹, Katinka Albrecht¹, Frank Buttgereit², Martin Aringer³, Guido Hoese⁴, Wolfgang Ochs⁵, Katja Thiele¹ and Angela Zink^1,2, ¹Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ²Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ³Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany, ⁴Rheumatologische Fachpraxis Stadthagen, Stadthagen, Germany, ⁵Internistisch-rheumatologische Praxisgemeinschaft Bayreuth, Bayreuth, Germany
Background/Purpose: Methods: Conclusion:
Abstract Number: 909 • 2016 ACR/ARHP Annual Meeting
A “Yellow Card” Reporting System for Sight Loss in Giant Cell Arteritis
Bhaskar Dasgupta¹, Asad Khan¹, Dimos Merinopoulos¹, Siwalik Banerjee², Dawn Gayford³, Philip Stapleton¹, Faidra Laskou¹ and Gianina Statache¹, ¹Rheumatology, Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ²Rheumatology, Southend University Hospital NHS Foundation Trust, Wescliff-on-Sea, United Kingdom, ³Rheumatology, Southend University Hospital NHS Foundation Trust, westcliff-on-Sea, United Kingdom
Background/Purpose: It is reported that 15-25% patients with GCA present with visual complications. Sight loss (SL) in the elderly is associated with considerable morbidity. There…
Abstract Number: 1231 • 2016 ACR/ARHP Annual Meeting
Impact of Comorbidity on Health-Related Quality of Life and Healthcare Expenditure in Patients with Rheumatoid Arthritis
Eric Nyarko¹ and J An², ¹College of Pharmacy, Western University of Health Sciences, Pomona, CA, ²Western University of Health Sciences, Pomona, CA
Background/Purpose: Rheumatoid Arthritis (RA) is known to be associated with an increased risk of comorbidity, premature mortality, and disability. We investigated the effect of comorbidity…
Abstract Number: 1235 • 2016 ACR/ARHP Annual Meeting
Healthcare Utilization and Multimorbidities Among Adult Patients with Juvenile Idiopathic Arthritis
Nina Mars¹, Anne M Kerola², Markku J Kauppi^3,4, Outi Elonheimo^5,6, Santeri Huvinen^5,6 and Tuulikki Sokka-Isler⁷, ¹University of Helsinki, Helsinki, Finland, ²Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ³School of Medicine, University of Tampere, Tampere, Finland, ⁴Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁵FCG Finnish Consulting Group Ltd., Helsinki, Finland, ⁶Network of Academic Health Centres, Department of Medicine, University of Helsinki, Helsinki, Finland, ⁷Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland
Background/Purpose: Active juvenile idiopathic arthritis (JIA) is commonly associated with high healthcare costs in children. The disabling consequences and multimorbidities often manifest, however, in adulthood.…
Abstract Number: 1480 • 2016 ACR/ARHP Annual Meeting
Determination of the Lipid Profile in Active Disease Leads to Incorrect Cardiovascular Risk Prediction in Early Rheumatoid Arthritis Patients
Samina A. Turk¹, Dirkjan van Schaardenburg^1,2, Willem F. Lems^1,3 and Mike T. Nurmohamed^1,3, ¹Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center, location Academic Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ³Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased cardiovascular morbidity and mortality. This cardiovascular risk is mainly determined by the lipid profile, which may change…
Abstract Number: 1552 • 2016 ACR/ARHP Annual Meeting
The Association of Fatigue, Comorbidities and Anti Rheumatic Drugs in Rheumatoid Arthritis: Results from French Cohort Study of Comorbidities
Anne Tournadre¹, Bruno Pereira², Laure Gossec³, Martin Soubrier⁴ and Maxime Dougados⁵, ¹Rheumatology, UNH-UMR 1019 INRA University of Auvergne and Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ²Biostatistics unit (DRCI), CHU Gabriel Montpied, Clermont-Ferrand, France, ³Sorbonne Universités, UPMC University Paris 06, Paris, France, Paris, France, ⁴Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ⁵Paris-Descartes University, Paris, France
Background/Purpose: The mechanisms of fatigue in rheumatoid arthritis (RA) are still unclear and the effect of antirheumatic drugs on fatigue not fully established. Objectives: To…
Abstract Number: 1770 • 2016 ACR/ARHP Annual Meeting
The Impact of Comorbidities on Quality of Life in Systemic Lupus Erythematosus in the First 10 Years
Murray Urowitz¹, Dafna D Gladman², Nicole Anderson³, Jiandong Su⁴ and The Systemic Lupus International Collaborating Clinics (SLICC) Group , ¹Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
The Impact of Comorbidities on Quality of Life in Systemic Lupus Erythematosus in the first 10 years Background/Purpose: The Medical Outcome Survey Short Form…
Abstract Number: 1790 • 2016 ACR/ARHP Annual Meeting
Accrual of Disease Comorbidities over 8 Years in a Multicentre Inception SLE Cohort
Murray Urowitz¹, Dafna D Gladman², Nicole Anderson³, Jiandong Su⁴ and The Systemic Lupus International Collaborating Clinics (SLICC) Group, ¹Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: The annual accrual of comorbidities in patients with SLE is not well described. We report the annual occurrence of these features in an inception…
Abstract Number: 2348 • 2016 ACR/ARHP Annual Meeting
Does Arthritis in Other Joints and Spine Influence the 1-Year Outcome of Total Hip Replacement? a Prospective European Multicenter Cohort Study Measuring the Influence of Musculoskeletal Morbidity
Joerg Huber¹, Paul Dieppe², Karsten Dreinhoefer³, Klaus-Peter Günther⁴, Georg Ruflin⁵ and Andrew Judge⁶, ¹Orthopedics, Triemli Spital, Zurich, Switzerland, ²Exeter Medical School, University of Exeter, Exeter, United Kingdom, ³Centre of Musculosceletal Surgery, Charité, Charite, Berlin, Berlin, Germany, ⁴University Center of Orthopedics and Traumatology, Technische Universität, Dresden, Germany, ⁵Orthopedics, Kantonsspital Aarau, Aarau, Switzerland, ⁶Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom
Background/Purpose: Whilst arthritis in other affected joints and back pain is known to lead to worse outcomes following total hip replacement surgery, these risk factors…
Abstract Number: 2759 • 2016 ACR/ARHP Annual Meeting
Prevalence of Comorbidities and Risk Factors of Spondyloarthritis in Latin America: A Comparative Study with the General Population: Data from the Multinational ASAS-Comospa Study
WILSON BAUTISTA-MOLANO^1,2, Robert Landewé³, Anna Molto⁴, Rubén Burgos-Vargas⁵, José Antonio Maldonado-Cocco⁶, Rafael Valle-Oñate⁷ and Désirée van der Heijde⁸, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology Department, School of Medicine, UMNG / HMC, Bogotá, Colombia, ³Amsterdam Medical Center, Amsterdam, Netherlands, ⁴Hopital Cochin, Paris Descartes University, Paris, France, ⁵Rheumatology, Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ⁶Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁷Rheumatology Department, School of Medicine, UMNG / HMC, Bogota, Colombia, ⁸Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Increased risk of several comorbidities has been reported in spondyloarthritis (SpA). Data and knowledge regarding the prevalence of these comorbidities and risk factors in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].